Related Experiment Video

Updated: Aug 20, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Overproduction of BCR-ABL induces apoptosis in imatinib mesylate-resistant cell lines

Vanessa Desplat1, Francis Belloc, Valérie Lagarde

  • 1Laboratoire Hematopoïése normale et pathologique FRE CNRS 2617, Université Victor Ségalen, Bordeaux Cedex, France.

Cancer
|November 24, 2004
PubMed
Abstract

Insights

Removing imatinib from culture induced apoptosis in chronic myeloid leukemia cells overexpressing BCR-ABL. This finding suggests a strategy to sensitize resistant cells to other drugs.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Imatinib mesylate is a BCR-ABL tyrosine kinase inhibitor used for chronic myeloid leukemia (CML).
  • BCR-ABL overexpression is a primary mechanism of imatinib resistance in CML.
  • Developing strategies to overcome imatinib resistance is crucial for effective CML treatment.

Purpose of the Study:

  • To investigate the correlation between BCR-ABL overexpression and apoptosis in imatinib-resistant CML cell lines.
  • To compare the response of resistant cell lines to imatinib withdrawal with their sensitive counterparts.
  • To explore potential therapeutic strategies for imatinib-resistant CML.

Main Methods:

  • Utilized BaF/BCR-ABL and LAMA84 cell lines, both resistant and sensitive to imatinib.
  • Investigated the effects of imatinib withdrawal on BCR-ABL protein expression and apoptosis.
  • Assessed apoptosis through caspase activation, annexin V staining, and mitochondrial potential changes.
  • Examined the role of STAT5/Bcl-xL and Akt kinase pathways.

Main Results:

  • Imatinib withdrawal led to decreased BCR-ABL protein expression in resistant cells for over 3 weeks.
  • Apoptosis, characterized by caspase activation and membrane changes, was observed in resistant cells after 3 days of imatinib deprivation.
  • STAT5/Bcl-xL pathway activation and Akt kinase activity preceded the apoptotic response.
  • Sensitive cell lines showed different responses to imatinib withdrawal (data not shown in abstract).

Conclusions:

  • Imatinib removal effectively induces apoptosis in BCR-ABL-overexpressing CML cells.
  • This phenomenon offers a potential method to sensitize imatinib-resistant CML cells to other cytotoxic drugs.
  • Further research could explore combination therapies involving imatinib withdrawal and other agents.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...